$CYAD #CELYAD CELYAD | Two allogeneic platforms to speed up a CAR: Celyad is leveraging its expertise in CAR-T development to progress both allogeneic and autologous therapies, with the cornerstone approach of using NKG2D receptor to… https://t.co/ldCgW8HwK9 #equity #stocks https://t.co/Xl7yDgbin6